CAS: 132097-09-7; 2,4-Dichloro-3-Methylpyridine

相似化合物

56961-78-5 18368-76-8 83791-90-6

上下游产品

CAS号74-88-4 碘甲烷 | CAS号26452-80-2 2,4-二氯吡啶 | CAS号91668-83-6 2-氯-3-甲基吡啶-N-氮氧化物 | CAS号18368-76-8 2-氯-3-甲基吡啶 | CAS号945543-26-0 3-(bromomethyl)...

碘甲烷置于正丁基锂体系中,用 四氢呋喃,正己烷 用作溶剂,化学反应 1.5H,以72%的收率获得2,4-二氯-3-甲基吡啶
参考文献: Trisubstituted Aryl And Heteroaryl Derivatives As Modulators Of Metabolism And The Prophylaxis And Treatment Of Disorders Related Thereto[fr] Derives Aryles Et Heteroaryles Trisubstitues Utilises En Tant Que Modulateurs Du Metabolisme Et Prophylaxie Et Traitement De Troubles Afferents
标题: Trisubstituted Aryl And Heteroaryl Derivatives As Modulators Of Metabolism And The Prophylaxis And Treatment Of Disorders Related Thereto[fr] Derives Aryles Et Heteroaryles Trisubstitues Utilises En Tant Que Modulateurs Du Metabolisme Et Prophylaxie Et Traitement De Troubles Afferents
摘要:本发明涉及公式(i)的某些三取代芳基和杂环芳基衍生物,它们是代谢调节剂.因此,本发明的化合物在预防或治疗代谢紊乱及其并发症,如糖尿病和肥胖方面是有用的.

专利信息

专利号:WO-2023091726-A1
优先权日:2021-11-18
标题:Inhibitors of cyclin‑dependent kinase 12 (cdk12)
发明人：BENOIT GUILLAUME; CARULLI JOHN; CHEN FEI; CHUAQUI CLAUDIO; CIBLAT STEPHANE; COOPER ELLIOT; DAGENAIS ROBIN; HU SHANHU; KABRO ANZHELIKA; LAPLACA DEREK; MARINEAU JASON; MOEBIUS DAVID; MOON DIANE; SOLODININ ANDREI; WHITMORE KENNETH
权利人:SYROS PHARMACEUTICALS INC
摘要:The present invention provides chemical compounds that inhibit one or more families of kinases (e.g., serine/threonine kinases, including one or more of the families of CDK proteins, and in particular, CDK12). More specifically, the present invention provides CDK12 inhibitors, of formula (I), pharmaceutically acceptable salts and isotopically labeled derivatives thereof, pharmaceutical compositions containing the compounds/inhibitors, and methods of their synthesis and use in treating proliferative diseases (e.g., a bladder cancer, a breast cancer, Ewing's sarcoma, a gastric cancer, a gastrointestinal cancer, a hematologic cancer, a lung cancer (e.g., small cell lung cancer (SCLC)), an ovarian cancer (e.g., a high grade serous ovarian cancer), a pancreatic cancer (e.g., pancreatic ductal adenocarcinoma (PDAC)), a brain cancer (e.g., glioblastoma), or a prostate cancer), alone or in combination with a second therapeutic agent. The proliferative disease can be a cancer, benign neoplasm, or pathologic angiogenesis, and any of the therapeutic methods or uses described herein can include a step of diagnosing the patient's disease. In other embodiments of the invention, the compositions described herein (e.g., the compounds, pharmaceutical compositions, and kits containing them) are used for the treatment of myotonic dystrophy (type 1 or type 2).

专利号:WO-2023156599-A1
优先权日:2022-02-18
标 题 :Synthesis of bruton's tyrosine kinase inhibitors